RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Trinity Biotech Stock

Trinity Biotech Liabilities 2024

Trinity Biotech Liabilities

83.38 M USD

Ticker

TRIB

ISIN

US8964383066

WKN

A0ET3S

In 2024, Trinity Biotech's total liabilities amounted to 83.38 M USD, a -11.56% difference from the 94.28 M USD total liabilities in the previous year.

Trinity Biotech Aktienanalyse

What does Trinity Biotech do?

Trinity Biotech PLC is a company specialized in the development, production, and marketing of diagnostic tests for infectious diseases, autoimmune diseases, and cancer. The company was founded in 1992 by Ronan O'Caoimh, an experienced manager in the diagnostics industry. Trinity Biotech has continuously expanded its business and is now recognized as one of the leading companies in the industry worldwide. Its business strategy is based on the development and marketing of diagnostic tests utilizing the latest technology and research. The company has a strong focus on continuous research and development of new products and technologies. Trinity Biotech operates in three main divisions: infectious diseases, autoimmune diseases, and cancer diagnostics. The company offers tests for various infectious diseases such as HIV, hepatitis, and tuberculosis in the infectious diseases division. The autoimmune diseases division develops and produces diagnostic tests for autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's syndrome. The cancer diagnostics division offers tests for various types of cancer such as breast cancer, prostate cancer, and colon cancer. Trinity Biotech's key products include the Uni-Gold HIV test, the TrinScreen Hepatitis C test, and the Uni-Gold S. pneumoniae test. These tests are highly accurate and reliable diagnostic tools used by clinics and laboratories worldwide. Trinity Biotech has a global presence with offices in North America, Europe, Asia, and the Middle East. The company is committed to providing its customers with the best possible diagnostic technology and support. Overall, Trinity Biotech is a renowned company in the diagnostics industry focused on developing innovative diagnostic tests for infectious diseases, autoimmune diseases, and cancer. With its strong R&D department, wide range of products, and global presence, Trinity Biotech will continue to play a leading role in the industry. Trinity Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Trinity Biotech's Liabilities

Trinity Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Trinity Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Trinity Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Trinity Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Trinity Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Trinity Biotech stock

What is the level of liabilities of Trinity Biotech this year?

Trinity Biotech has a debt balance of 83.38 M USD this year.

What were the liabilities of Trinity Biotech compared to the previous year?

The liabilities of Trinity Biotech have increased by -11.56% dropped compared to the previous year.

What are the consequences of high debt for investors of Trinity Biotech?

High liabilities can pose a risk for investors of Trinity Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Trinity Biotech?

Low liabilities mean that Trinity Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Trinity Biotech affect the company?

An increase in liabilities of Trinity Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Trinity Biotech affect the company?

A decrease in the liabilities of Trinity Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Trinity Biotech?

Some factors that can influence the liabilities of Trinity Biotech include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Trinity Biotech so important for investors?

The liabilities of Trinity Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Trinity Biotech take to modify the liabilities?

To change its liabilities, Trinity Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Trinity Biotech pay?

Over the past 12 months, Trinity Biotech paid a dividend of 0.22 USD . This corresponds to a dividend yield of about 16.92 %. For the coming 12 months, Trinity Biotech is expected to pay a dividend of -0.27 USD.

What is the dividend yield of Trinity Biotech?

The current dividend yield of Trinity Biotech is 16.92 %.

When does Trinity Biotech pay dividends?

Trinity Biotech pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Trinity Biotech?

Trinity Biotech paid dividends every year for the past 0 years.

What is the dividend of Trinity Biotech?

For the upcoming 12 months, dividends amounting to -0.27 USD are expected. This corresponds to a dividend yield of -20.68 %.

In which sector is Trinity Biotech located?

Trinity Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trinity Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trinity Biotech from 7/1/2015 amounting to 0.22 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2015.

When did Trinity Biotech pay the last dividend?

The last dividend was paid out on 7/1/2015.

What was the dividend of Trinity Biotech in the year 2023?

In the year 2023, Trinity Biotech distributed 0 USD as dividends.

In which currency does Trinity Biotech pay out the dividend?

The dividends of Trinity Biotech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Trinity Biotech stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Trinity Biotech

Our stock analysis for Trinity Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trinity Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.